142 related articles for article (PubMed ID: 33048394)
21. Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer.
Ola IO; Talala K; Tammela T; Taari K; Murtola T; Kujala P; Raitanen J; Auvinen A
Int J Cancer; 2023 Feb; 152(4):672-678. PubMed ID: 36056577
[TBL] [Abstract][Full Text] [Related]
22. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
Villers A; Bessaoud F; Trétarre B; Grosclaude P; Malavaud B; Rebillard X; Iborra F; Daubisse L; Malavaud S; Roobol M; Heijnsdijk EA; de Koning HJ; Hugosson J; Rischmann P; Soulié M
Prog Urol; 2020 Apr; 30(5):252-260. PubMed ID: 32197936
[TBL] [Abstract][Full Text] [Related]
23. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
Hugosson J; Roobol MJ; Månsson M; Tammela TLJ; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Carlsson SV; Talala KM; Lilja H; Denis LJ; Recker F; Paez A; Puliti D; Villers A; Rebillard X; Kilpeläinen TP; Stenman UH; Godtman RA; Stinesen Kollberg K; Moss SM; Kujala P; Taari K; Huber A; van der Kwast T; Heijnsdijk EA; Bangma C; De Koning HJ; Schröder FH; Auvinen A;
Eur Urol; 2019 Jul; 76(1):43-51. PubMed ID: 30824296
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.
Frånlund M; Arnsrud Godtman R; Carlsson SV; Lilja H; Månsson M; Stranne J; Hugosson J
Scand J Urol; 2018 Aug; 52(4):256-262. PubMed ID: 30241447
[TBL] [Abstract][Full Text] [Related]
25. False-positive screening results in the Finnish prostate cancer screening trial.
Kilpeläinen TP; Tammela TL; Määttänen L; Kujala P; Stenman UH; Ala-Opas M; Murtola TJ; Auvinen A
Br J Cancer; 2010 Feb; 102(3):469-74. PubMed ID: 20051951
[TBL] [Abstract][Full Text] [Related]
26. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
[TBL] [Abstract][Full Text] [Related]
27. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
[TBL] [Abstract][Full Text] [Related]
28. Second round results of the Finnish population-based prostate cancer screening trial.
Mäkinen T; Tammela TL; Stenman UH; Määttänen L; Aro J; Juusela H; Martikainen P; Hakama M; Auvinen A
Clin Cancer Res; 2004 Apr; 10(7):2231-6. PubMed ID: 15073097
[TBL] [Abstract][Full Text] [Related]
29. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.
Wu GH; Auvinen A; Yen AM; Hakama M; Tammela TL; Stenman UH; Kujala P; Ruutu M; Chen HH
Eur Urol; 2012 May; 61(5):1011-8. PubMed ID: 22264679
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of prostate cancer screening among men using antidiabetic medication.
Vettenranta A; Murtola TJ; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Sci Rep; 2021 Apr; 11(1):7363. PubMed ID: 33795720
[TBL] [Abstract][Full Text] [Related]
31. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH; Hugosson J; Carlsson S; Tammela T; Määttänen L; Auvinen A; Kwiatkowski M; Recker F; Roobol MJ
Eur Urol; 2012 Nov; 62(5):745-52. PubMed ID: 22704366
[TBL] [Abstract][Full Text] [Related]
32. Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality.
Zhu X; van Leeuwen PJ; Holmberg E; Bul M; Carlsson S; Schröder FH; Roobol MJ; Hugosson J
J Med Screen; 2012 Sep; 19(3):133-40. PubMed ID: 23093731
[TBL] [Abstract][Full Text] [Related]
33. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
van Leeuwen PJ; Kranse R; Hakulinen T; Hugosson J; Tammela TL; Ciatto S; Roobol MJ; Zappa M; de Koning HJ; Bangma CH; Moss SM; Auvinen A; Schröder FH
J Med Screen; 2013 Mar; 20(1):33-38. PubMed ID: 28075228
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
35. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
[TBL] [Abstract][Full Text] [Related]
36. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):483-490. PubMed ID: 30696944
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
38. Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial.
Frånlund M; Månsson M; Godtman RA; Aus G; Holmberg E; Kollberg KS; Lodding P; Pihl CG; Stranne J; Lilja H; Hugosson J
J Urol; 2022 Aug; 208(2):292-300. PubMed ID: 35422134
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
[TBL] [Abstract][Full Text] [Related]
40. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
